PD-1/PD-L1 inhibitors can block the pathway and restore the immune response of T cells to tumors and its efficacy has been widely proven in the treatment of various malignant tumors such as NSCLC and melanoma [8, 9]. This evidence concerns the gene PDCD1 and melanoma.